|Professor||David||Brooks||MRC Clinical Sciences Centre||UK|
|Institution||MRC Clinical Sciences Centre|
|Street Address||Imperial College London, Hammersmith Hospital Campus, Du Cane Road|
- United Kingdom
Medical Research Council
- Parkinson’s disease
- Huntington’s disease
To investigate in vivo with PET/MRI activation and PET ligand studies:
* The functional anatomy of motor control in health and disease and its modulation by incentives and aversive stimuli.
* Changes in release of dopamine and other modulatory neurotransmitters, and opening of voltage gated ion channels during different aspects of motor function.
* The dysfunctional anatomy and transmitter release underlying bradykinesia and involuntary movements in Parkinson’s and Huntington’s diseases and dystonias.
* Central mechanisms of adaptation to lesions of the basal ganglia and motor pathways.
* Resting patterns of altered dopa and glucose metabolism and receptor binding underlying idiopathic and genetic forms of Parkinson’s disease, atypical parkinsonian disorders, and involuntary movement disorders
* The glial response to cortical and subcortical neurodegenerations.
* Levels of abnormal protein aggregation (beta amyloid, tau, synuclein deposition) in cortical and subcortical dementias. Using PET as a biomarker, to determine in vivo the efficacy of:
* Putative neuroprotective agents in modifying progression of subcortical degenerations disorders and influencing glial activation and amyloid deposition.
*Nerve growth factors in restoring function in Parkinson’s disease and, in the future, other subcortical neurodegenerations.
* Cell implants (fetal midbrain and striatal/retinal pigment epithelial/carotid body/transformed fibroblasts/neural progenitor) in restoring function in Parkinson’s and Huntington’s diseases.